Defining clinically relevant responses in erectile function: an SMSNA position statement.

Area of Science:

• Urology
• Clinical Trials
• Medical Device Evaluation

Background:

• Existing scoring systems inadequately define clinical efficacy for erectile dysfunction (ED) therapies.
• Lack of standardized criteria hinders comparison between ED treatment cohorts and in meta-analytic studies.

Purpose of the Study:

• To establish minimal criteria for defining clinical efficacy in ED therapies.
• To provide a framework for evaluating treatment effectiveness in clinical trials and meta-analyses.

Main Methods:

• An analytic review of standardized ED questionnaires, focusing on the International Index of Erectile Function, Erectile Function Domain (IIEF-EFD).
• Analysis of the minimally clinically important difference (MCID) concept for ED treatment evaluation.
• Development of recommendations for best practices in clinical trials to assess ED therapy efficacy.

Main Results:

• The International Index of Erectile Function, Erectile Function Domain (IIEF-EFD) is the preferred tool for assessing ED treatment outcomes.
• Investigational ED therapies must demonstrate MCID in prospective, randomized, placebo-controlled trials.
• New methods proposed for calculating adjusted MCID in mixed-severity ED populations and for meta-analytic studies.

Conclusions:

• The developed framework provides evidence-based criteria to define clinically effective ED therapies.
• This guidance aids decision-makers, clinicians, and patients in differentiating effective ED treatments.
• Addresses ambiguities in published literature regarding MCID for ED therapies.